drug_type
RELEVANT_DRUG
intervention_type
Gene-modified autologous TCR-T cellular therapy
drug_description
An individualized, autologous, gene-modified TCR-T cellular immunotherapy. Patient T cells are engineered ex vivo to express a tumor-specific T-cell receptor identified from the patient’s lesion and then reinfused to mediate HLA-restricted recognition of tumor peptide antigens, triggering TCR/CD3 signaling, activation, proliferation, and perforin/granzyme-dependent cytotoxic killing of tumor cells in refractory/relapsed solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Immunotherapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells are gene-modified ex vivo to express a tumor-specific T-cell receptor. After reinfusion, these TCR-T cells recognize peptide antigens presented by patient HLA on tumor cells, initiating TCR/CD3 signaling, activation and expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of tumor cells.
drug_name
KSX01-TCRT
nct_id_drug_ref
NCT05811975